| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
B p50/p65 and Fra-1 and JunD Is Essential for Deregulated Interleukin 6 Expression in Prostate Cancer1
BIDMC Genomics Center and New England Baptist Bone and Joint Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115
To date, no effective treatment for patients with advanced androgen-independent prostate cancer is available, whereas androgen ablation therapy, surgery, and radiation therapy are effective in treating local, androgen-dependent tumors. The mechanisms underlying the differences between androgen-dependent and -independent prostate cancer remain elusive. Interleukin (IL)-6 is a pleiotropic cytokine whose expression under normal physiological conditions is tightly controlled. However, aberrant constitutive IL-6 gene expression has been implicated in prostate cancer progression and resistance to chemotherapy and has been directly linked to prostate cancer morbidity and mortality. Particularly striking is the large increase in the expression of IL-6 in hormone-refractory prostate cancer. IL-6, in addition to its role as an immunomodulatory cytokine, functions as a growth and differentiation factor for prostate cancer cells. To determine the molecular mechanisms that lead to deregulated IL-6 expression in advanced prostate cancer, we examined the regulatory elements involved in IL-6 gene expression in androgen-independent prostate cancer cells. We demonstrate that, in contrast to the androgen-sensitive LNCaP cells, androgen-insensitive PC-3 and DU145 cells express high levels of IL-6 protein and mRNA due to enhanced promoter activity. Deregulated activation of the IL-6 promoter is for the most part mediated by a combined constitutive activation of the nuclear factor (NF)-
B p50 and p65 and the activator protein 1 (AP-1) JunD and Fra-1 family members as demonstrated by electrophoretic mobility shift assays, site-directed mutagenesis, and transfection experiments. Mutation of the NF-B and AP-1 sites drastically reduces IL-6 promoter activity in both androgen-independent prostate cancer cell lines. Additionally, inhibition of these transcription factors using adenovirus vectors encoding either the IB
repressor gene or a dominant negative JunD mutant leads to a strong down-regulation of IL-6 gene expression at the mRNA and protein level as measured by real-time PCR and ELISA, respectively. Furthermore, the blockade of IL-6 gene expression results in drastic inhibition of the constitutively activated signal transducers and activators of transcription 3 signaling pathway in DU145 cells. Our data demonstrate for the first time that a combined aberrant activation of NF-B p50 and p65 and AP-1 JunD and Fra-1 in androgen-independent prostate cancer cells results in deregulated IL-6 expression, suggesting a novel potential entry point for therapeutic intervention in prostate cancer.
This article has been cited by other articles:
|
|
 |
|
  H.-Z. Sun, T.-W. Yang, W.-J. Zang, and S.-F. Wu Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway J. Endocrinol., March 1, 2010; 204(3): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Ndlovu, C. Van Lint, K. Van Wesemael, P. Callebert, D. Chalbos, G. Haegeman, and W. Vanden Berghe Hyperactivated NF-{kappa}B and AP-1 Transcription Factors Promote Highly Accessible Chromatin and Constitutive Transcription across the Interleukin-6 Gene Promoter in Metastatic Breast Cancer Cells Mol. Cell. Biol., October 15, 2009; 29(20): 5488 - 5504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishiguro, K. Akimoto, Y. Nagashima, Y. Kojima, T. Sasaki, Y. Ishiguro-Imagawa, N. Nakaigawa, S. Ohno, Y. Kubota, and H. Uemura aPKC{lambda}/{iota} promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6 PNAS, September 22, 2009; 106(38): 16369 - 16374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. PITULIS, E. PAPAGEORGIOU, R. TENTA, P. LEMBESSIS, and M. KOUTSILIERIS IL-6 and PPAR{gamma} Signalling in Human PC-3 Prostate Cancer Cells Anticancer Res, June 1, 2009; 29(6): 2331 - 2337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. I. Heath, D. W. Hillman, U. Vaishampayan, S. Sheng, F. Sarkar, F. Harper, M. Gaskins, H. C. Pitot, W. Tan, S. P. Ivy, et al. A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7940 - 7946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Spentzos, S. A Cannistra, F. Grall, D. A Levine, K. Pillay, T. A Libermann, and C. S Mantzoros IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer Endocr. Relat. Cancer, September 1, 2007; 14(3): 781 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guruvayoorappan and G. Kuttan {beta}-Carotene Inhibits Tumor-Specific Angiogenesis by Altering the Cytokine Profile and Inhibits the Nuclear Translocation of Transcription Factors in B16F-10 Melanoma Cells Integr Cancer Ther, September 1, 2007; 6(3): 258 - 270. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Sun, Y. Tang, X. Lou, L. Zhu, K. Yang, B. Zhang, H. Shi, and C. Wang UXT is a novel and essential cofactor in the NF-{kappa}B transcriptional enhanceosome J. Cell Biol., July 10, 2007; 178(2): 231 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Tesz, A. Guilherme, K. V. P. Guntur, A. C. Hubbard, X. Tang, A. Chawla, and M. P. Czech Tumor Necrosis Factor {alpha} (TNF{alpha}) Stimulates Map4k4 Expression through TNF{alpha} Receptor 1 Signaling to c-Jun and Activating Transcription Factor 2 J. Biol. Chem., July 6, 2007; 282(27): 19302 - 19312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guruvayoorappan and G. Kuttan Effect of Amentoflavone on the Inhibition of Pulmonary Metastasis Induced by B16F-10 Melanoma Cells in C57BL/6 Mice Integr Cancer Ther, June 1, 2007; 6(2): 185 - 197. [Abstract] [PDF]
|
|
|
|
 |
|
 X. Gu, L. F. Zerbini, H. H. Otu, M. Bhasin, Q. Yang, M. G. Joseph, F. Grall, T. Onatunde, R. G. Correa, and T. A. Libermann Reduced PDEF Expression Increases Invasion and Expression of Mesenchymal Genes in Prostate Cancer Cells Cancer Res., May 1, 2007; 67(9): 4219 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M.R. Bhuiyan, Y. Li, S. Banerjee, F. Ahmed, Z. Wang, S. Ali, and F. H. Sarkar Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells. Cancer Res., October 15, 2006; 66(20): 10064 - 10072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Uzzo, P. L. Crispen, K. Golovine, P. Makhov, E. M. Horwitz, and V. M. Kolenko Diverse effects of zinc on NF-{kappa}B and AP-1 transcription factors: implications for prostate cancer progression Carcinogenesis, October 1, 2006; 27(10): 1980 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, C. Montagut, M. Tapia, C. Campas, L. Dang, et al. Interleukin 6, a Nuclear Factor-{kappa}B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-{kappa}B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. Clin. Cancer Res., September 15, 2006; 12(18): 5578 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nonn, L. Peng, D. Feldman, and D. M. Peehl Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells via Mitogen-Activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D. Cancer Res., April 15, 2006; 66(8): 4516 - 4524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Asirvatham, M. Schmidt, B. Gao, and J. Chaudhary Androgens Regulate the Immune/Inflammatory Response and Cell Survival Pathways in Rat Ventral Prostate Epithelial Cells Endocrinology, January 1, 2006; 147(1): 257 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ijiri, L. F. Zerbini, H. Peng, R. G. Correa, B. Lu, N. Walsh, Y. Zhao, N. Taniguchi, X.-L. Huang, H. Otu, et al. A Novel Role for GADD45{beta} as a Mediator of MMP-13 Gene Expression during Chondrocyte Terminal Differentiation J. Biol. Chem., November 18, 2005; 280(46): 38544 - 38555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J.M. Best, J. W. Gillespie, Y. Yi, G. V.R. Chandramouli, M. A. Perlmutter, Y. Gathright, H. S. Erickson, L. Georgevich, M. A. Tangrea, P. H. Duray, et al. Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy Clin. Cancer Res., October 1, 2005; 11(19): 6823 - 6834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. F. Zerbini and T. A. Libermann GADD45 Deregulation in Cancer: Frequently Methylated Tumor Suppressors and Potential Therapeutic Targets Clin. Cancer Res., September 15, 2005; 11(18): 6409 - 6413. [Full Text] [PDF]
|
|
|
|
|
|
Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Park, M. D.M. Huq, X. Hu, and L.-N. Wei Tyrosine Nitration on p65: A Novel Mechanism to Rapidly Inactivate Nuclear Factor-{kappa}B Mol. Cell. Proteomics, March 1, 2005; 4(3): 300 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Montaner, A. Sodhi, J.-M. Servitja, A. K. Ramsdell, A. Barac, E. T. Sawai, and J. S. Gutkind The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia Blood, November 1, 2004; 104(9): 2903 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. F. Zerbini, Y. Wang, A. Czibere, R. G. Correa, J.-Y. Cho, K. Ijiri, W. Wei, M. Joseph, X. Gu, F. Grall, et al. NF-{kappa}B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45{alpha} and {gamma} is essential for cancer cell survival PNAS, September 14, 2004; 101(37): 13618 - 13623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sivashanmugam, L. Tang, and Y. Daaka Interleukin 6 Mediates the Lysophosphatidic Acid-regulated Cross-talk between Stromal and Epithelial Prostate Cancer Cells J. Biol. Chem., May 14, 2004; 279(20): 21154 - 21159. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
